140 related articles for article (PubMed ID: 2872037)
41. High efficacy of monomethoxypolyethylene glycol-conjugated L-asparaginase (PEG2-ASP) in two patients with hematological malignancies.
Kawashima K; Takeshima H; Higashi Y; Hamaguchi M; Sugie H; Imamura I; Wada H
Leuk Res; 1991; 15(6):525-30. PubMed ID: 1861535
[TBL] [Abstract][Full Text] [Related]
42. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
[TBL] [Abstract][Full Text] [Related]
43. A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma.
Muss HB; Spell N; Scudiery D; Capizzi RL; Cooper MR; Cruz J; Jackson DV; Richards F; Spurr CL; White DR
Invest New Drugs; 1990 Feb; 8(1):125-30. PubMed ID: 2345067
[TBL] [Abstract][Full Text] [Related]
44. Modified pharmacokinetics of I-asparaginase from E coli by formation of specific antibodies to I-Asparaginase of different immunoglobulin classes in children with acute lymphocytic leukemia.
Wahn V; Fabry U; Körholz D; Reinhardt D; Jürgens H; Göbel U
Pediatr Pharmacol (New York); 1983; 3(3-4):303-11. PubMed ID: 6377216
[TBL] [Abstract][Full Text] [Related]
45. Response to highly purified L-asparaginase during therapy of acute leukemia.
Hill JM; Loeb E; MacLellan A; Khan A; Roberts J; Shields WF; Hill NO
Cancer Res; 1969 Aug; 29(8):1574-80. PubMed ID: 4896902
[No Abstract] [Full Text] [Related]
46. [L-asparaginase in blast leukemia].
Georgiev Z; Genova V; Avramova D
Vutr Boles; 1973; 12(6):25-37. PubMed ID: 4522152
[No Abstract] [Full Text] [Related]
47. Antitumor activity and other biologic properties of L-asparaginase (NSC-109229)-a review.
Adamson RH; Fabro S
Cancer Chemother Rep; 1968 Oct; 52(6):617-26. PubMed ID: 4895425
[No Abstract] [Full Text] [Related]
48. Immunological effects of native and polyethylene glycol-modified asparaginases from Vibrio succinogenes and Escherichia coli in normal and tumour-bearing mice.
Bendich A; Kafkewitz D; Abuchowski A; Davis FF
Clin Exp Immunol; 1982 Apr; 48(1):273-8. PubMed ID: 7044632
[TBL] [Abstract][Full Text] [Related]
49. Use of the polyethylene glycol adduct of L-asparaginase for the treatment of hyperasparaginemia in a schizophrenic patient.
Perry TL; Wright JM; Hansen S; Davis FF; Abuchowski A
Biol Psychiatry; 1985 Oct; 20(10):1103-8. PubMed ID: 4041512
[TBL] [Abstract][Full Text] [Related]
50. Asparaginase inhibits the lectin pathway of complement activation.
Keizer MP; Aarts C; Kamp AM; Caron HN; van de Wetering MD; Wouters D; Kuijpers TW
Mol Immunol; 2018 Jan; 93():189-192. PubMed ID: 29197742
[TBL] [Abstract][Full Text] [Related]
51. Biocmical and pharmacologic effects of L-asparaginase in man.
Haskell CM; Canellos GP; Cooney DA; Hansen HH
J Lab Clin Med; 1970 May; 75(5):763-70. PubMed ID: 4909251
[No Abstract] [Full Text] [Related]
52. Production of a novel N-terminal PEGylated crisantaspase.
Torres-Obreque K; Meneguetti GP; Custódio D; Monteiro G; Pessoa-Junior A; de Oliveira Rangel-Yagui C
Biotechnol Appl Biochem; 2019 May; 66(3):281-289. PubMed ID: 30597637
[TBL] [Abstract][Full Text] [Related]
53. Antitumor enzyme: polyethylene glycol-modified asparaginase.
Wada H; Imamura I; Sako M; Katagiri S; Tarui S; Nishimura H; Inada Y
Ann N Y Acad Sci; 1990; 613():95-108. PubMed ID: 2076022
[No Abstract] [Full Text] [Related]
54. Phase I study of L-asparaginase (NSC 109229).
Wilson WL; Weiss AJ; Ramirez G
Oncology; 1975; 32(3-4):109-17. PubMed ID: 768851
[TBL] [Abstract][Full Text] [Related]
55. [Amino acid concentration in plasma and blood cells during coli-L-asparaginase therapy].
Höcker P; Stacher A; Weiser M
Blut; 1972 Jul; 25(1):9-19. PubMed ID: 4505116
[No Abstract] [Full Text] [Related]
56. Polyethylene Glycol Acts as a Mechanistic Stabilizer of L-asparaginase: A Computational Probing.
Sindhu R; Pradeep H; Manonmani HK
Med Chem; 2019; 15(6):705-714. PubMed ID: 30727907
[TBL] [Abstract][Full Text] [Related]
57. Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells.
Kravtzoff R; Desbois I; Lamagnere JP; Muh JP; Valat C; Chassaigne M; Colombat P; Ropars C
Eur J Clin Pharmacol; 1996; 49(6):465-70. PubMed ID: 8706771
[TBL] [Abstract][Full Text] [Related]
58. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.
Abuchowski A; Kazo GM; Verhoest CR; Van Es T; Kafkewitz D; Nucci ML; Viau AT; Davis FF
Cancer Biochem Biophys; 1984 Jun; 7(2):175-86. PubMed ID: 6467175
[TBL] [Abstract][Full Text] [Related]
59. Chemical modification of L-asparaginase with a comb-shaped copolymer of polyethylene glycol derivative and maleic anhydride.
Kodera Y; Tanaka H; Matsushima A; Inada Y
Biochem Biophys Res Commun; 1992 Apr; 184(1):144-8. PubMed ID: 1567419
[TBL] [Abstract][Full Text] [Related]
60. Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia.
Agrawal V; Woo JH; Borthakur G; Kantarjian H; Frankel AE
Protein Pept Lett; 2013 Apr; 20(4):392-402. PubMed ID: 23016580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
